Author

A. Cingoz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:ChIP-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Assay:bulk RNA-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

T. Bagci-Onder· 4 shared A. P. Cribbs· 3 shared A. C. Aksu· 2 shared E. Yilmaz· 2 shared F. Seker-Polat· 2 shared H. Syed· 2 shared M. Philpott· 2 shared N. A. Lack· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

T. Bagci-Onder

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer

O. Yedier-Bayram, A. Cingoz, E. Yilmaz, A. C. Aksu, B. Esin, N. Pinarbasi Degirmenci, A. D. Cavga, B. Dedeoglu, B. Cevatemre, H. Syed, M. Philpott, A. P. Cribbs, U. Oppermann, N. Lack, C. ACILAN AYHAN, , T. Bagci-Onder

The paper identifies BRPF1 as a key regulator of Taxol resistance in TNBC through genetic and chemical screens, showing its inhibition sensitizes resistant cells to chemotherapy.

bioRxiv · Apr 16, 2024Cancer Biology

HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex

S. Lingadahalli, B. E. Fazlioglu, U. B. Altintas, A. Cingoz, E. Tekoglu, I. P. L. Yu, H. Andomat, I. Kulac, T. Morova, K. Xiao, U. M. Dikbas, M. Gleave, L. Fazli, P. Cejas, H. Long, , N. A. Lack

This study shows HOXB13 promotes prostate cancer proliferation by altering chromatin accessibility through interactions with the SWI/SNF complex, particularly in AR-negative castration-resistant prostate cancer.

bioRxiv · Sep 4, 2023 · PreprintCancer Biology

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology